The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 30, 2018

Filed:

Sep. 23, 2016
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Roger Johns, Reisterstown, MD (US);

Xingwu Teng, Baltimore, MD (US);

Dechun Li, Perry Hall, MD (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 17/02 (2006.01); A61K 38/22 (2006.01); A61K 38/17 (2006.01); C07K 16/22 (2006.01); G01N 33/50 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61K 9/00 (2006.01); C07K 14/575 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1709 (2013.01); A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); G01N 33/5061 (2013.01); A61K 48/00 (2013.01); C07K 2317/20 (2013.01);
Abstract

We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor (HIMF). HIMF strongly activated Akt phosphorylation. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 inhibits HIMF-activated Akt phosphorylation. It also inhibits HIMF-stimulated RPSM proliferation. Thus, the PI3K/Akt pathway, at least in part, mediates the proliferative effect of HIMF. HIMF also has angiogenic and vasoconstrictive activity. Notably, HIMF increases pulmonary arterial pressure and vascular resistance more potently than either endothelin-1 or angiotensin II.


Find Patent Forward Citations

Loading…